Qscreen AI Announces Strategic U.S. Engagement to Drive Innovation in Public Safety and Institutional Health
Toronto, Ontario--(Newsfile Corp. - February 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), a pioneering leader in artificial intelligence enabled health and safety technology, is pleased to announce that it has entered into an independent contractor agreement with Global Frontier Advisors L.P. ("GFA"), effective January 30, 2026. GFA will receive a combination of equity-based along with performance-based compensation during the term of the agreement, subject to applicabl
2026-02-09 7:01 AM EST | QScreen AI Inc.
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme. The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised cl
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-09 7:00 AM EST | Optimi Health Corp.
Cheelcare Announces $1.0 Million Unsecured Note Financing
Markham, Ontario--(Newsfile Corp. - February 9, 2026) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced that it has entered into term sheets with strategic investors for a non-brokered unsecured promissory note (the "Notes") financing for gross proceeds of up to $1,000,000 (the "Offering"). The Offering is expected to include $750,000 from Pathfinder Asset Management Ltd. ("PAML") and $
2026-02-09 7:00 AM EST | Cheelcare Inc.
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents". The international patent application covers innovative methods and formulations aimed at ad
Biotechnology, Pharmaceuticals, Health
2026-02-09 3:00 AM EST | PreveCeutical Medical Inc.
Apollo Biowellness, Inc., Announces Termination of Distribution Agreement with Revive Regenerative, Inc.
North Bergen, New Jersey--(Newsfile Corp. - February 6, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company), announces that the 'Exclusive Distribution Agreement' dated July 1, 2025, between Evolutionary Biologics (a wholly owned subsidiary of Apollo Biowellness) and Revive Regenerative, Inc. ("Revive") has been "terminated for cause" by Evolutionary Biologics, for reasons already disclosed to Revive Regenerative, Inc. and is no longer in effect.
Household / Consumer / Cosmetics, Health
2026-02-06 9:30 AM EST | Apollo Biowellness, Inc.
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national i
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-06 3:00 AM EST | TempraMed Technologies Ltd.
NuGen Medical Devices Inc. Provides Update on Health Canada License
Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse of its license with Health Canada. The Company's Health Canada Licence became expired due to an untimely certificate renewal. This is not a suspension or cancellation related to regulatory compliance or enforcement action. The temporary status does not constitute a product safety
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-05 5:15 PM EST | NuGen Medical Devices Inc.
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - February 5, 2026) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On February 4, 2026, the Issuer completed an additional tranche (the "Current Tranche") of a private placement of units ("Units") announced on January 30, 2025. 650,970 Unit
Technology, Healthcare and Hospitals, Health
2026-02-05 4:52 PM EST | James Anderson
Orange Auto Insurance, Inc., Subsidiary of HPN Holdings, Inc. Announces Reinsurance Partnership
Chicago, Illinois--(Newsfile Corp. - February 5, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or the "Company") today announced that its subsidiary Orange Auto Insurance, Inc ("Orange"), a technology-driven nonstandard automobile insurance holding company and its managing general agency (Orange Underwriters, LLC) have obtained the reinsurance capacity to begin operations. The reinsurance and reinsurer partnership will provide Orange with the capacity to write up to $25 million in pr
2026-02-05 10:04 AM EST | HPN Holdings, Inc.
MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - February 4, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the eleventh of the Offering, consists of 650,970 Units of the Company (the "
Technology, Healthcare and Hospitals, Health
2026-02-04 6:00 PM EST | MyndTec Inc.
This World Cancer Day, St. Baldrick's Foundation Leads the Charge Against Childhood Cancer
Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is shining a light on the urgent need for continued investment in childhood cancer research, and on the powerful global community working together to accelerate cures and develop better, safer treatments for children facing cancer. Wor
2026-02-04 2:00 PM EST | St. Baldrick's Foundation
Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification. The Form 10, originally filed on December 5, 2025, was not subject to furt
Healthcare and Hospitals, Health
2026-02-04 9:32 AM EST | Adia Nutrition Inc.
Bloom Burton & Co. Announces the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2026 Bloom Burton Award and to open nomination submissions from the public at large on or before March 27, 2026. The finalists for the 2026 Bloom Burton Award will be announced at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from April 21-22, 2026.
Technology, Biotechnology, Investment Banking, Health
2026-02-04 8:25 AM EST | Bloom Burton & Co. Inc.
Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 annou
2026-02-04 8:00 AM EST | Izotropic Corporation
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a breakthrough intracellular delivery technology d
Biotechnology, Pharmaceuticals, Health
2026-02-04 3:15 AM EST | Defence Therapeutics Inc.
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-03 5:30 PM EST | Medexus Pharmaceuticals Inc.
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant. "Since 2006, the first question I have
Biotechnology, Pharmaceuticals, Health
2026-02-03 8:55 AM EST | Hemostemix Inc.
Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy
Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the expansion of its MOD™ and .decimal™ brands into Manitoba, alongside an expansion of its product portfolio in New Brunswick. These developments represent another step forward in the Company's national expansion strategy and build on the strong commercial momentum established in 2025. Expanding N
2026-02-03 7:30 AM EST | Glow Lifetech Corp.
Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review
New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today announced the publication of an observational case report documenting late-onset hair regrowth and related physical observations in a 49-year-old male subject, Muhammad Qasim. The published case report presents a structured, non-clinical record compiled over an extended observation period. The documentation includes longitudinal v
2026-02-03 4:43 AM EST | Case Reports in Regrowth
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury sha
Healthcare and Hospitals, Health
2026-02-03 1:10 AM EST | Cosmo Pharmaceuticals N.V.